{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T19:23:58Z","timestamp":1785612238469,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["RS2017A001030879"],"award-info":[{"award-number":["RS2017A001030879"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Retinoblastoma is an ocular tumor in infants with cancer predisposition. Treatment of the rare tumor needs to be optimized for ocular preserved survival without second primary malignancy (SPM).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We studied the outcomes of all patients with retinoblastoma at a tertiary center in 1984\u20132016, when preservation method changed from radiotherapy (1984\u20132001) to systemic chemotherapy (2002\u20132016).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>One-hundred sixteen infants developed unilateral- (<jats:italic>n<\/jats:italic>\u2009=\u200977), bilateral- (<jats:italic>n<\/jats:italic>\u2009=\u200938), or trilateral-onset (<jats:italic>n<\/jats:italic>\u2009=\u20091) tumor. Ten (8.6%) had a positive family history, despite a few studies on <jats:italic>RB1<\/jats:italic> gene. Contralateral disease occurred in one unilateral-onset case. One-hundred eight of 155 eyes (70%) were enucleated. Nine binocular survivors were from 5 bilateral- and 4 unilateral-onset cases. Two survivors received bilateral enucleation. Six deaths occurred; brain involvement (including 3 trilateral diseases) in 4 bilateral-onset, systemic invasion in a unilateral-onset, and SPM (osteosarcoma) in a bilateral-onset case(s). Two others survived SPM of osteosarcoma or lymphoma. The 10-year overall survival (OS: 98.5% vs. 91.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.068) and binocular survivors (13.2% vs. 5.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.154) between bilateral- and unilateral-onsets did not differ statistically. The 10-year OS and cancer (retinoblastoma\/SPM)-free survival (CFS) rates of all patients were 94.9 and 88.5%, respectively. The proportion of preserved eyes did not differ between radiotherapy and chemotherapy eras. The CFS rate of bilateral-onset cases in systemic chemotherapy era was higher than that in radiotherapy era (<jats:italic>p<\/jats:italic>\u2009=\u20090.042). The CFS rates of bilateral-onset patients with neoadjuvant chemotherapy (upfront systemic therapy for preservation) was higher than those without it (<jats:italic>p<\/jats:italic>\u2009=\u20090.030).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Systemic chemotherapy and local therapy raised OS and binocular survival rates of bilateral-onset patients similarly to those of unilateral-onset patients. All but one death was associated with a probable germline defect of the <jats:italic>RB1<\/jats:italic> gene. Neoadjuvant stratified chemotherapy may support the long-term binocular life with minimized risk of SPM.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12887-020-1923-7","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T08:02:39Z","timestamp":1580198559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Survival and ocular preservation in a long-term cohort of Japanese patients with retinoblastoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Tamaki","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-9988","authenticated-orcid":false,"given":"Yuhki","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Yamana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utako","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamasa","family":"Yoshitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiji","family":"Ohga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouichi","family":"Ohga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"1923_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/1078-0432.CCR-17-0652","volume":"23","author":"J Kamihara","year":"2017","unstructured":"Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Moss\u00e9 YP, Nakagawara A, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017;23:98\u2013106.","journal-title":"Clin Cancer Res"},{"key":"1923_CR2","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1136\/bjo.2008.150292","volume":"93","author":"T Kivel\u00e4","year":"2009","unstructured":"Kivel\u00e4 T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93:1129\u201331.","journal-title":"Br J Ophthalmol"},{"key":"1923_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-med-061312-123455","volume":"65","author":"DH Abramson","year":"2014","unstructured":"Abramson DH. Retinoblastoma: saving life with vision. Annu Rev Med. 2014;65:171\u201384.","journal-title":"Annu Rev Med"},{"key":"1923_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41388-017-0050-x","volume":"37","author":"ID Fabian","year":"2018","unstructured":"Fabian ID, Onadim Z, Karaa E, Duncan C, Chowdhury T, Scheimberg I, et al. The management of retinoblastoma. Oncogene. 2018;37:1551\u201360.","journal-title":"Oncogene."},{"issue":"5","key":"1923_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jamaophthalmol.2016.0244","volume":"134","author":"YA Yousef","year":"2016","unstructured":"Yousef YA, Soliman SE, Astudillo PPP, Durairaj P, Dimaras H, Chan HSL, et al. Intra-arterial chemotherapy for retinoblastoma: a systematic review. JAMA Ophthalmol. 2016;134(5):584\u201391. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.0244.","journal-title":"JAMA Ophthalmol"},{"key":"1923_CR6","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2011.03.013","volume":"118","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081\u20137.","journal-title":"Ophthalmology."},{"key":"1923_CR7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.ophtha.2014.01.026","volume":"121","author":"CL Shields","year":"2014","unstructured":"Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453\u201360.","journal-title":"Ophthalmology."},{"key":"1923_CR8","doi-asserted-by":"publisher","unstructured":"Abramson DH, Shields CL, Jabbour P, Teixeira LF, Fonseca JRF, Marques MCP, et al. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. Int J Retin Vitr. 2017;3(40). https:\/\/doi.org\/10.1186\/s40942-017-0093-8.","DOI":"10.1186\/s40942-017-0093-8"},{"key":"1923_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12887-016-0579-9","volume":"16","author":"SGA Selistre","year":"2016","unstructured":"Selistre SGA, Maestri MK, Santos-Silva P, Sch\u00fcler-Faccini L, Guimar\u00e3es LSP, Giacomazzi J, et al. Retinoblastoma in a pediatric oncology reference center in southern Brazil. BMC Pediatr. 2016;16:48. https:\/\/doi.org\/10.1186\/s12887-016-0579-9.","journal-title":"BMC Pediatr"},{"key":"1923_CR10","doi-asserted-by":"publisher","unstructured":"Hu H, Zhang W, Wang Y, Huang D, Huang D, Shi J, et al. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC Ophthalmol. 2018;18(107). https:\/\/doi.org\/10.1186\/s12886-018-0772-8.","DOI":"10.1186\/s12886-018-0772-8"},{"key":"1923_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10384-018-0597-2","volume":"62","author":"The committee for the national registry of retinoblastoma","year":"2018","unstructured":"The committee for the national registry of retinoblastoma. The national registry of retinoblastoma in Japan (1983\u20132014). Jpn J Ophthalmol. 2018;62:409\u201323.","journal-title":"Jpn J Ophthalmol"},{"key":"1923_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3928\/01913913-20140513-01","volume":"51","author":"S Okimoto","year":"2014","unstructured":"Okimoto S, Nomura K. Clinical manifestations and treatment of retinoblastoma in Kobe children\u2019s hospital for 16 years. J Pediatr Ophthalmol Strabismus. 2014;51:222\u20139.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1923_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/pbc.20606","volume":"47","author":"G Chantada","year":"2006","unstructured":"Chantada G, Doz F, Antoneli CB, Grundy R, Clare Stannard FF, Dunkel IJ, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47:801\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"1923_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/13816810802452168","volume":"30","author":"DE Novetsky","year":"2009","unstructured":"Novetsky DE, Abramson DH, Kim JW, Dunkel IJ. Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies--an analysis of impact. Ophthalmic Genet. 2009;30:40\u20134.","journal-title":"Ophthalmic Genet"},{"key":"1923_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pbc.26193","volume":"64","author":"P Temming","year":"2017","unstructured":"Temming P, Wieland R, J\u00f6ckel K, Eisele L, Le Guin CH, Sch\u00fcndeln MM, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors : a report from the German reference center. Pediatr Blood Cancer. 2017;64:71\u201380.","journal-title":"Pediatr Blood Cancer"},{"key":"1923_CR16","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2013.54.7844","volume":"32","author":"JR Wong","year":"2014","unstructured":"Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN, Kleinerman RA. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32:3284\u201390.","journal-title":"J Clin Oncol"},{"key":"1923_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/13816810.2016.1244695","volume":"38","author":"DH Abramson","year":"2017","unstructured":"Abramson DH, Fabius AW, Francis JH, Marr BP, Dunkel IJ, Brodie SE, et al. Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma. Ophthalmic Genet. 2017;38:16\u201321.","journal-title":"Ophthalmic Genet"},{"key":"1923_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/08820538.2016.1154177","volume":"31","author":"G Singh","year":"2016","unstructured":"Singh G, Daniels AB. Disparities in retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries. Semin Ophthalmol. 2016;31:310\u20136.","journal-title":"Semin Ophthalmol"},{"key":"1923_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/bjo.2008.154427","volume":"93","author":"SG Honavar","year":"2009","unstructured":"Honavar SG. Emerging options in the management of advanced intraocular retinoblastoma. Br J Ophthalmol. 2009;93:848\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1923_CR20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/archopht.119.9.1269","volume":"119","author":"CL Shields","year":"2001","unstructured":"Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol. 2001;119:1269\u201372.","journal-title":"Arch Ophthalmol"},{"key":"1923_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/jjco\/hyq201","volume":"41","author":"Y Araki","year":"2011","unstructured":"Araki Y, Matsuyama Y, Kobayashi Y, Toyokawa S, Inoue K, Suzuki S, Makimoto A. Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan. Jpn J Clin Oncol. 2011;41:373\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"1923_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1007\/s10147-018-1303-6","volume":"23","author":"Y Ishida","year":"2018","unstructured":"Ishida Y, Maeda M, Adachi S, Inada H, Kawaguchi H, Hori H, et al. Secondary cancer after a childhood cancer diagnosis : viewpoints considering primary cancer. Int J Clin Oncol. 2018;23:1178\u201388.","journal-title":"Int J Clin Oncol"},{"key":"1923_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/petr.12321","volume":"18","author":"D Caselli","year":"2014","unstructured":"Caselli D, Tamburini A, La Torre A, Pollazzi L, Tintori V, Bambi F, et al. High-dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma : report of five cases. Pediatr Transplant. 2014;18:631\u20136.","journal-title":"Pediatr Transplant"},{"key":"1923_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044322","volume":"7","author":"YP Gobin","year":"2012","unstructured":"Gobin YP, Dunkel IJ, Marr BP, Francis JH, Brodie SE, Abramson DH. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One. 2012;7:e44322. https:\/\/doi.org\/10.1371\/journal.pone.0044322.","journal-title":"PLoS One"},{"key":"1923_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/apjon.apjon_18_17","volume":"4","author":"TT Kivel\u00e4","year":"2017","unstructured":"Kivel\u00e4 TT, Hadjistilianou T. Neonatal retinoblastoma. Asia Pac J Oncol Nurs. 2017;4:197\u2013204.","journal-title":"Asia Pac J Oncol Nurs"},{"key":"1923_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature10733","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Benavente CA, Mcevoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481:329\u201334.","journal-title":"Nature"},{"key":"1923_CR27","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1167\/iovs.18-24359","volume":"59","author":"ZK Goldsmith","year":"2018","unstructured":"Goldsmith ZK, Coppess W, Irvine AS, Yuan K, Barsh SR, Ritter MK, et al. Targeting the platelet-derived growth factor-beta stimulatory circuitry to control retinoblastoma seeds. Invest Ophthalmol Vis Sci. 2018;59:4486\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1923_CR28","first-page":"8424","volume":"15","author":"LI Li","year":"2018","unstructured":"Li LI, Chen WEI, Wang Y, Tang L, Han M. Long non-coding RNA H19 regulates viability and metastasis, and is upregulated in retinoblastoma. Oncol Lett. 2018;15:8424\u201332.","journal-title":"Oncol Lett"},{"key":"1923_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ophtha.2017.09.001","volume":"125","author":"AH Skalet","year":"2018","unstructured":"Skalet AH, Gombos DS, Gallie BL, Kim JW, Shields CL, Marr BP, et al. Screening children at risk for retinoblastoma consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018;125:453\u20138.","journal-title":"Ophthalmology."}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-1923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12887-020-1923-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-1923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:10:30Z","timestamp":1611706230000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-020-1923-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1923"],"URL":"https:\/\/doi.org\/10.1186\/s12887-020-1923-7","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"22 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was certified by the Institutional Review Board of Kyushu University (#29\u2013244). This study is a retrospective study, and most of the subjects are those who have completed follow-ups in pediatrics and ophthalmology, and those who visit about once a year even during follow-up.It is not possible to conduct individual explanations on research using explanatory documents and obtain consent and conduct research.Therefore, an explanatory document regarding this research will be sent at the same time as the questionnaire, and the consent of the research participation will be given by returning the questionnaire.In addition, information on this study will be made public on the homepage for those who cannot move the questionnaire due to moving away.Based on the above requirements, this study has obtained the informed consent of patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}